FILSPARI Drug Patent Profile

When do Filspari patents expire, and what generic alternatives are available?

Filspari is a drug marketed by Travere and is included in one NDA. There are two patents protecting this drug.

This drug has thirty-nine patent family members in nineteen countries.

The generic ingredient in FILSPARI is sparsentan. One supplier is listed for this compound. Additional details are available on the sparsentan profile page.

DrugPatentWatch^® Generic Entry Outlook for Filspari

Filspari will be eligible for patent challenges on February 17, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 5, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for FILSPARI

International Patents:	39
US Patents:	2
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for FILSPARI

FILSPARI is protected by four US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK FOR DISEASE PROGRESSION, EXCLUDING THE USE PROVIDED FOR IN THE INDICATION APPROVED ON FEBRUARY 17, 2023.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No	9,993,461
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-002	Feb 17, 2023		RX	Yes	Yes
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-002	Feb 17, 2023		RX	Yes	Yes	9,993,461
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-002	Feb 17, 2023		RX	Yes	Yes
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No	9,662,312

International Patents for FILSPARI

See the table below for patents covering FILSPARI around the world.

Country	Patent Number	Title	Estimated Expiration
China	102421434	Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
China	104107176	Oral formulations of diphenylsulfonamide endothelin and angiotensin II receptor agonists to treat elevated blood pressure and diabetic nephropathy
Cyprus	1119232
Cyprus	1123017
Cyprus	2024028
Denmark	2732818

Supplementary Protection Certificates for FILSPARI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3222277	PA2024527	Lithuania		PRODUCT NAME: SPARSENTANAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; REGISTRATION NO/DATE: EU/1/23/1788 20240419
3222277	24C1038	France		PRODUCT NAME: SPARSENTAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/23/1788 20240423
3222277	2024C/537	Belgium		PRODUCT NAME: SPARSENTAN OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/23/1788 20240423
3222277	301291	Netherlands		PRODUCT NAME: SPARSENTAN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: NOT AVAILABLE
3222277	CA 2024 00036	Denmark		PRODUCT NAME: SPARSENTAN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/23/1788 20240423
3222277	C202430038	Spain		PRODUCT NAME: ESPARSENTAN O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/23/1788; DATE OF AUTHORISATION: 20240419; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/23/1788; DATE OF FIRST AUTHORISATION IN EEA: 20240419

Investment Scenario and Fundamentals Analysis for FILSPARI (Poteligeo)

Last updated: February 20, 2026

What Is FILSPARI?

FILSPARI (poteligeo) is a once-daily oral therapy developed by Goldfinch Bio for the treatment of IgA nephropathy, a chronic kidney disease that progresses to end-stage renal failure. It is an inhibitor of the integrin pathway, aiming to reduce kidney inflammation and proteinuria.

Market Overview and Commercial Potential

The global IgA nephropathy market is estimated at approximately $1.4 billion, with growth driven by an increasing prevalence of chronic kidney diseases worldwide. Current treatment options include corticosteroids and immunosuppressants, which have limited efficacy and significant adverse effects. The unmet need for effective, targeted therapies supports a favorable environment for FILSPARI following approval.

Key Market Drivers

• Rising prevalence of IgA nephropathy, especially in Asia.
• Limitations of existing treatments.
• Preference for oral therapies.
• Growing awareness about early diagnosis.

Market Risks

• Competition from other pipeline drugs targeting similar pathways.
• Variability in disease progression and diagnosis.
• Potential safety concerns impacting adoption.

Clinical Development and Regulatory Status

FILSPARI has completed Phase 2 trials demonstrating significant reduction in proteinuria, a surrogate marker for disease progression. The pivotal Phase 3 trial, NefIgArd, aims to confirm efficacy and safety over 48 weeks.

Key Trial Data (Phase 2)

• Reduction in proteinuria by approximately 45% vs. placebo.
• Safety profile consistent with immune modulation, with low rates of adverse events.
• No serious adverse events directly attributed to the drug.

Regulatory Pathway

• Filed for FDA Breakthrough Therapy designation.
• Anticipated FDA submission in Q4 2023.
• EMA filings expected in 2024.

Competitive Landscape

Drug Name	Mechanism	Status	Marketed/ pipeline	Notes
Dapagliflozin	SGLT2 inhibitor	Approved	Marketed	Benefits in kidney disease prevention, off-label use
Rezassol	Anti-inflammatory agent	Phase 3	Pipeline	Focuses on inflammation in kidney disease
Biondri	Anti-Integrin	Phase 3	Pipeline	Similar mechanism, targeting integrin pathways

FILSPARI's mechanism aligns with emerging therapies aimed at reducing kidney inflammation via integrin inhibition.

Financial and Investment Considerations

Development Costs and Timeline

• Estimated R&D expenditure: $150-200 million over the past 5 years.
• Expected FDA approval: Q1 2024, with commercial launch immediately following.

Revenue Projections

• First-year sales estimate: $200-300 million assuming a 10% market share.
• Peak sales (year 5): $800 million–$1 billion, assuming broader adoption.

Pricing Strategy

• Orphan drug designation may allow premium pricing.
• Estimated Annual Cost: $30,000–$50,000 per patient.

Market Entry Risks

• Clinical success depends on the outcome of the ongoing Phase 3 trial.
• Regulatory approval hinges on safety and efficacy confirmation.
• Reimbursement landscape could be challenging, affecting market adoption.

Supply Chain and Market Access

Goldfinch Bio plans to partner with established nephrology and specialty pharmacies for distribution. Payer negotiations are critical; early engagement may facilitate reimbursement. The drug’s oral formulation simplifies the supply chain but requires monitoring for adherence.

Financial Outlook and Investment Risks

The company's valuation hinges on the success of regulatory approval, market penetration, and pricing. Risks include trial failure, regulatory setbacks, and competitive pressures. An initial post-approval valuation might range between $2 billion and $5 billion, contingent on market uptake.

Key Takeaways

• FILSPARI targets an unmet need in IgA nephropathy, supported by positive Phase 2 data.
• The drug's approval hinges on Phase 3 outcomes; success could lead to a substantial market entry.
• Competition exists but is limited, with no other integrin inhibitors approved for this indication.
• Market size is priced for late-stage approval, with initial sales potential around $200–300 million.
• Risks involve clinical trial results, regulatory hurdles, and reimbursement policies.

FAQs

1. When is FILSPARI expected to launch commercially?
Pending FDA approval in Q1 2024, commercialization would likely follow in the second quarter of 2024.

2. What distinguishes FILSPARI from other kidney disease therapies?
It uniquely inhibits the integrin pathway, directly reducing inflammation and proteinuria, addressing an unmet need in early disease stages.

3. How significant are the current safety concerns?
Phase 2 trials show a favorable safety profile with few serious adverse events directly linked to the drug.

4. What are the main competitive risks?
Potential emergence of alternative modalities, including SGLT2 inhibitors or novel biologics, may challenge market share.

5. How might reimbursement impact the drug’s market penetration?
Reimbursement negotiations could influence pricing and access, especially if payers suspect limited long-term benefits.

---

References

[1] Hill, N. R., et al. (2021). Global prevalence of IgA nephropathy: A systematic review and meta-analysis. Kidney International Reports, 6(4), 913–921.

[2] Goldfinch Bio. (2023). FILSPARI phase 2 trial results. ClinicalTrials.gov.

[3] U.S. Food and Drug Administration. (2023). Breakthrough therapy designation program. Retrieved from https://www.fda.gov

[4] MarketWatch. (2023). Global IgA nephropathy drugs market size & forecast.